HarryZ wrote:As one study showed, 327 MS patients using Interferon studied over 21 years show a 46.8 % reduction in hazard of mortality over palcebo!! So instead of 10 MS patients dying in any one group, only 6 patients would have died if they took Interferon. And what the heck does this mean when it comes to living with MS?!!
David1949 wrote:
Association Between Use of Interferon Beta and Progression of Disability in Patients With Relapsing-Remitting Multiple Sclerosis
(Of the CRAB drugs, R, A and B are interferon beta drugs and were mentioned in the study)
The study’s Conclusion: Among patients with relapsing-remitting MS, administration of interferon beta was not associated with a reduction in progression of disability.
http://jama.jamanetwork.com/article.asp ... id=1217239
The first link is about mortality in treated vs. untreated MSers and the second link is about the benefits of
early treatment. I'm sure that there are studies that focus on quality of life, but that's not what the links are about.
HarryZ wrote:The comparison was done with patients who used a placebo (of unknown nature). Why wasn't a comparison done with patients who used nothing or perhaps alternative medicine? The very nature of MS being remitting and relapsing kind of makes these studies irrelevant unless of course you are the one selling Interferon to MS patients.
A placebo is an inert substance that has no effect whatsoever on the medical condition being studied, in other words, the patients were using nothing. As far as the nature of the placebo used, the researchers may have used saline. The results for an alternative medicine would have been about the same as using a placebo. If an alternative medication is shown to be effective in randomized, double-blind trials, then it's no longer alternative, just regular, conventional medication.
HarryZ wrote:The very nature of MS being remitting and relapsing kind of makes these studies irrelevant unless of course you are the one selling Interferon to MS patients.
That depends on a study's time-frame. Results at six months is meaningless (regardless if the intervention used is a drug or surgery) but results at 21 years is not.
HarryZ wrote:I guess this is why the FDA has fined all of the drug companies who make the CRABs at some point as they have published false and erroneous information and videos about how well their drugs help MS patients.
David1949 wrote:The “C” drug is not interferon beta. But the makers of the drug received a warning letter from the FDA for “false and misleading messages”. The warning letter also stated that “C… is not approved by the FDA for slowing, preventing or reversing physical disability associated with relapsing-remitting multiple sclerosis.”
http://copaxone.com/redirect/Copaxone.c ... Letter.pdf
The FDA doesn't only fine drug companies. They also fine medical device companies and supplement companies, both of which fall under its purview. And just to be clear, being fined does not mean that the treatment is flawed. Drug and medical device companies just cannot make a claim about a treatment that wasn't shown in research studies. Supplements are, for some reason, treated differently.
HarryZ wrote:When it comes to making a buck, there doesn't appear to be any barriers to prevent some people from saying and doing whatever it takes, regardless of the consequences.
That's why the FDA exists. If I had a complaint about them, it would be that they are far too lenient on the supplement industry (which according to Forbes, makes a billion dollars each year) despite the fact that serious adverse events have been associated with some supplements. And legally, they can make any unproven claim that they want just as long as they have a warning label stating that any claims made have not be evaluated by the FDA somewhere on the bottle. Yes, the FDA is not perfect, but it's better than doing nothing.
David1949 wrote:A study reported by Fox News states:
Benefit of MS Drugs Comes at Steep Price, Study Finds
Actually, Katia Noyes' research supports the WebMDs article on early treatment. Her comment:
In the case of DMDs for MS, she said, starting earlier in the course of the disease appears to be better.
Professor George Ebers was an outspoken critic of the NHS' treatment scheme mentioned in the news article from the Independent. He's also one of the authors of the mortality study linked in my original post.